Something unusual is happening in healthcare right now. A class of medications that existed quietly for years, used primarily for type 2 diabetes, has become one of the most talked-about pharmaceutical developments in a generation. GLP-1 drugs are prescribed in volumes that supply chains are still struggling to meet. Waiting lists are long. The cultural conversation around them is loud, often reductive, and almost entirely focused on weight.

What that conversation is missing is the people actually using them.

Behind the headlines is a growing population of individuals who inject weekly, manage side effects, track doses, and navigate a healthcare system that is still catching up with the scale of demand. Many of them are doing this for the first time. They didn't grow up managing a condition with daily injections. They don't have the routines, the muscle memory, or the support infrastructure that longer-term insulin users have built over years.

And the tools available to them reflect that gap.

Most medication tracking apps were built for a different era and a different user. They assume familiarity with self-injection. They treat logging as an afterthought. They don't account for the specific anxieties of someone new to injecting, the questions about where to inject, how to rotate, what to do when a site feels different, whether what they're experiencing is normal.

This is the design opportunity. Not the drug itself, and not the weight loss narrative around it. The opportunity is in the experience of the millions of people now injecting regularly for the first time, who deserve tools built around how they actually live, not around a clinical workflow designed for someone else.

Drop was built for insulin users first. But the problems it solves, rotation tracking, dose logging, site management, building a sustainable habit around something you have to do every week without thinking about it too hard, map almost exactly onto what GLP-1 users need.

The GLP-1 boom is a cultural moment. But underneath it is something quieter and more durable: a generation of new injectors who are figuring this out as they go, with tools that weren't designed for them.